Metys Pharmaceuticals

Basel, Switzerland Founded: 2013 • Age: 13 yrs Acquired By Novaremed
Drugs for chemotherapy-induced peripheral neuropathy and CNS disorders are developed.

About Metys Pharmaceuticals

Metys Pharmaceuticals is a company based in Basel (Switzerland) founded in 2013 was acquired by Novaremed in September 2021.. Metys Pharmaceuticals offers products and services including Non-Opioid Pain Treatment Programs. Metys Pharmaceuticals operates in a competitive market with competitors including Jazz Pharmaceuticals, Lundbeck, Sana Biotechnology, Karuna Therapeutics and Kriya Therapeutics, among others.

  • Headquarter Basel, Switzerland
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Novaremed Ag
Operational Areas
Healthcare → Healthcare Products & Supplies
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Latest Funding Round
    $55.82 K (USD), Grant

    Apr 30, 2019

  • Investors
    Novaremed

    & 2 more

  • Employee Count
    Employee Count
  • Acquired by
    Novaremed

    (Sep 07, 2021)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Metys Pharmaceuticals

Metys Pharmaceuticals offers a comprehensive portfolio of products and services, including Non-Opioid Pain Treatment Programs. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Clinical and preclinical projects for managing chronic pain without opioids.

Funding Insights of Metys Pharmaceuticals

  • Total Funding
  • Total Rounds 2
  • Last Round Grant — $55,824
  • First Round

    (01 Jan 2019)

  • Investors Count 2
Date Amount Transaction Name Valuation Lead Investors Investors
Apr, 2019 Amount Grant - Metys Pharmaceuticals Valuation

investors

Jan, 2019 Amount Grant - Metys Pharmaceuticals Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Metys Pharmaceuticals

Metys Pharmaceuticals has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Novaremed, European Union and EIC Fund. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Government agency and accelerator focusing on innovative startups and SMEs
Founded Year Domain Location
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
Founded Year Domain Location
Tyrosine kinase modulators are developed for neuropathic pain treatment.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Metys Pharmaceuticals

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Metys Pharmaceuticals

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Metys Pharmaceuticals Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Metys Pharmaceuticals

Metys Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Lundbeck, Sana Biotechnology, Karuna Therapeutics and Kriya Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Novel biopharmaceutical medicines are developed for unmet medical needs.
domain founded_year HQ Location
Drugs for CNS disorders are developed and advanced.
domain founded_year HQ Location
Genetically engineered cell therapies are developed for multiple disorders.
domain founded_year HQ Location
Therapies for psychosis and cognitive impairment are developed.
domain founded_year HQ Location
Developer of therapeutic solutions for the treatment of diabetes
domain founded_year HQ Location
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Metys Pharmaceuticals

Frequently Asked Questions about Metys Pharmaceuticals

When was Metys Pharmaceuticals founded?

Metys Pharmaceuticals was founded in 2013 and raised its 1st funding round 6 years after it was founded.

Where is Metys Pharmaceuticals located?

Metys Pharmaceuticals is headquartered in Basel, Switzerland. It is registered at Basel, Basel-stadt, Switzerland.

What does Metys Pharmaceuticals do?

Metys Pharmaceuticals was founded in 2013 in Basel, Switzerland. The company is engaged in the pharmaceutical industry, with operations centered on developing therapies for chemotherapy-induced peripheral neuropathy and related central nervous system conditions. The primary candidate, MP-101, consists of a non-racemic combination of dimiracetam enantiomers. Focus is placed on advancing these treatments through research and clinical processes in the European market.

Who are the top competitors of Metys Pharmaceuticals?

Metys Pharmaceuticals's top competitors include Jazz Pharmaceuticals, Neurocrine and Biohaven Pharmaceutical.

What products or services does Metys Pharmaceuticals offer?

Metys Pharmaceuticals offers Non-Opioid Pain Treatment Programs.

Who are Metys Pharmaceuticals's investors?

Metys Pharmaceuticals has 3 investors. Key investors include Novaremed, European Union, and EIC Fund.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available